Publication
Amivantamab plus pembrolizumab in previously untreated recurrent/metastatic head and neck squamous cell cancer: Results from the phase 1b/2 OrigAMI-4 study.
Hsiang-Fong Kao, Kevin Harrington, Aarti Bhatia, Hung-Ming Wang, Malwinder S Sandhu, William Ince, Ewa Pawlowska, Zara Vidales, Marc Oliva, Ajay Mehta, Paul L Swiecicki, Myung-Ju Ahn, Ammar Sukari, Sung-Bae Kim, Jin-Ching Lin, Bhumsuk Keam, Xuesong Lyu, Joshua C Curtin, Kiichiro Toyoizumi, Mark Wade, Aastha Kapoor, Patricia Lorenzini, Emrullah Yilmaz, Mahadi Baig, Remy B Verheijen, Sujay Shah, Ranee Mehra
- Source
- PubMed
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-PUBMED-20260930-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
BACKGROUND: Prognosis is poor for patients with recurrent/metastatic (R/M) head and neck squamous cell cancer (HNSCC), warranting novel treatments. Epidermal growth factor receptor (EGFR) and MET are overexpressed in HNSCC and contribute to cancer progression and metastasis. Amivantamab, an…
Read on PubMedLinked entities
Linked entities (1)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 1
- trialNCT06385080registry_reference1.00
Registered trialsNCT06385080
Curated evidence
Evidence citing this paper (0)
Data not yet available